Published in Hepatitis Weekly, August 8th, 2005
"Treatment of chronic hepatitis C with interferon (IFN)-alpha and ribavirin has hematotoxic effects. We evaluated the effects of four different IFN/IFN-ribavirin treatment regimens on hematopoiesis. Hematopoiesis was studied in 133 patients with chronic hepatitis C receiving IFN-alpha 2b alone (group A) or in combination with ribavirin (group B), pegylated IFN-alpha 2a (group C), or pegylated IFN-alpha 2b (group D) in combination with ribavirin," researchers in Austria report.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.